CVS Following Our Technical Prescription
by Mike Paulenoff
November 7, 2021 • 4:55 PM EST
Early on October 15, when CVS Health Corporation (CVS) was trading at 85.92, Mike Paulenoff highlighted upside opportunity for MPTrader members, writing:
"For the past 5 months, CVS has gone pretty much nowhere after hitting a new 6 year high at 90.61 on 5/25/21. It is precisely because CVS has traversed a sideways price path since late May that makes my work interpret the CVS technical setup as extremely promising for a run above 90.61 towards 100, and possibly 108-110 in the upcoming weeks and months."
Mike again wrote positively about the stock on October 20, when it was trading at 86.45, commenting:
"If my intermediate-term technical work is telling us anything about CVS, it is saying, 'watch me rocket above 90 towards a 100+ target!' Only a failure to hurdle 87 followed by a decline beneath 82 will compromise the developing anticipated thrust to the upside."
CVS began climbing on October 26, taking out key resistance at its prior failed rally peak at 87.80, The stock continued to strengthen right into last week's earnings report on November 3, when the company beat the Street's estimates on earnings, revenues, and guidance, propelling the stock to 96.57, its highest price in over five years.
At that high, CVS was 12.4% above its price at Mike's initial alert.
What's next for CVS? The strength of the consumer and another round of Covid-19 (booster) shots tie into the strength of CVS, which according to Mike's technical setup work has unfinished business on the upside as it heads towards 100-102 next. But will there be a period of rest-digestion first?
Join Mike and our MPTrader members for ongoing intraday discussions about CVS, as well as many other stocks, macro indices, ETFs, cryptocurrencies, and commodities.
Last Tuesday afternoon, hours before CAVA (Cava Group) was scheduled to report Earnings, this is what I posted for MPTrader members:CAVA reports Earnings after today's close. Approaching the news, CAVA is circling 61, a full 40% beneath its April 2026 high at 98.79, amid an unconfirmed new corrective low at 60.21 yesterday (8/10/26), leaving CAVA positioned for a "buy-the-news" setup (the opposite of a sell-the-news setup in a name that is up 30% to 40% approaching Earnings).
Good Sunday Afternoon, MPTraders! Last Thursday afternoon, ahead of AAPL's Earnings, this is what we discussed about the stock's probable price path in reaction to the news:Unless AAPL produces something extraordinary, or otherwise announces some unknown bullish catalyst, my pattern work has a very difficult time expecting anything other than a "best-case" sell-the-news scenario in reaction to Earnings. I can make a compelling argument that the upleg from the 6/26/26 low at 273.33 to the 7/29/26 ATH at 344.
XOM (Exxon Mobil)-- Back on May 19, 2026, a fellow MPTrader member requested an update on XOM. This is what we discussed at that time:My attached Daily Chart setup shows my preferred scenario calling for a near-term peak of the current upmove from the 4/17 low at 141.97 to a target zone from 162 to 165, followed by a rollover and press lower that revisits and possibly breaks the 41/7 low, which also will complete the larger corrective process from the 3/30/26 ATH at 176.41.
Pharma Update: MRK and LLYOn Wednesday (6/24/26), this is what we discussed about MRK:MRK as well, which we see on my attached Daily Chart exhbits a VERY BULLISH technical setup-- quite the opposite of beleaguered PFE. My pattern work argues that all of the price action from the 2/25/26 high at 125.14 represents a high-level bullish digestion period and pattern atop the major upleg from the May 2025 low at 73.31.
On January 2, 2026, this is what I posted about CAVA (Cava Group Casual Mediterranean Cuisine) to MPTrader members:After CAVA's meteoric climb from 29.00 in October 2023 to an ATH at 172.65 in November 2024, the stock rolled over into a relentless decline that hit its low at 43.
